PITCHFORCE�APRIL 2023
PRESENTER: LLEWELLYN CASBOLT
RM191A: �A TRANSFORMATIVE SMALL MOLECULE COMPLEX
NEUROPATHIC PAIN
WOUND HEALING
PHYSICAL TRAUMA
NOT TO BE REPRODUCED WITHOUT PERMISSION OF RR MEDSCIENCES PTY LTD
WE BELIEVE �THAT PAIN MANAGEMENT AND HEALING ARE AT THE HEART OF MEDICINE
NEUROPATHIC PAIN
Physical trauma
Chemotherapy
Surgery
Diabetes
NEUROPATHIC PAIN
NEUROPATHIC PAIN
Global market forecast to reach�$25.2 billion ��by 2027, expanding at a compound annual growth rate (CAGR) of
12.9%
Source: The PharmaLetter May 2021 – based on research and analytics by GlobalData
NPRS: MEAN CHANGE IN AVERAGE PAIN INTENSITY
��
one of the most widely prescribed therapeutics �for treatment of neuropathic pain.
NOT TO BE REPRODUCED WITHOUT PERMISSION OF RR MEDSCIENCES PTY LTD
RM191A CLINICAL TRIAL RESULTS
RM191A NNT IS 6
This is equivalent to that
of pregabalin – Lyrica
PLATFORM OF APPLICATIONS
NOT TO BE REPRODUCED WITHOUT PERMISSION OF RR MEDSCIENCES PTY LTD
RM191A
Anti-ageing
RR MEDSCIENCES’ FOCUS
Mastectomy model: Endpoints: acute pain, wound healing, transition to NP and treatment of NP. Multi-centre study.
CLINICAL PHASE 2b/3: Neuropathic Pain (NP)
Rhinoplasty model: Endpoints: reduction in oedema and bruising; pain relief. Multi-centre study.
CLINICAL PHASE 2b: Post-Surgical Trauma
Post-translational research from Phase 2a trial. Research institute partner(s) to be confirmed.
POST-TRANSLATIONAL RESEARCH
NOT TO BE REPRODUCED WITHOUT PERMISSION OF RR MEDSCIENCES PTY LTD
RR MEDSCIENCES’ FOCUS
Mastectomy model: Endpoints: acute pain, wound healing, transition to NP and treatment of NP. Multi-centre study.
CLINICAL PHASE 2b/3: Neuropathic Pain (NP)
Rhinoplasty model: Endpoints: reduction in oedema and bruising; pain relief. Multi-centre study.
CLINICAL PHASE 2b: Post-Surgical Trauma
NOT TO BE REPRODUCED WITHOUT PERMISSION OF RR MEDSCIENCES PTY LTD
POST-MASTECTOMY
NOT TO BE REPRODUCED WITHOUT PERMISSION OF RR MEDSCIENCES PTY LTD
Aim: �to prevent �neuropathic pain and improve healing
RM191A AND IMPACT TRAUMA: A CASE STUDY
23 December, 2018 - 6:41pm
Time: 0
NOT TO BE REPRODUCED WITHOUT PERMISSION OF RR MEDSCIENCES PTY LTD
OUR TEAM
Professor Paul Glare�Lead Investigator | Pain Trial
�University of Sydney Medical School
Chair: Pain Medicine
Catherine Eddy�Chief Financial Officer��CFO, CA, CPA�Entrepreneurial businesses
Llewellyn Casbolt�Chief Executive Officer�
Leadership roles in corporate �and entrepreneurial environments �in Australia, USA, UK
Successful ASX MedTech IPO
Dr Abhirup Das�Chief Scientific Officer�
Stanford PhD�Harvard Med Post Doc
University of New South Wales
Sofia Casbolt
Strategy & Operations��10+ years operations, logistics, management and strategic planning experience in the health and pharmaceutical sector
TIMELINE
NOT TO BE REPRODUCED WITHOUT PERMISSION OF RR MEDSCIENCES PTY LTD
RRMed �will be cash burn Years 1 – 4 �as we implement �our clinical program
Typical pharma �deal, successful �Phase 2b/3 drug: �US$1–10 billion
Preferred exit �is sale/license to �large pharma
Anticipate 15 – 20x for investors at exit
YEARS 1 – 3
IMPLEMENT CLINICAL TRIALS
YEARS 3 – 3.5
CONCLUDE TRIALS, ANALYSE AND PUBLISH DATA
YEARS 3.5 – 4
BEGIN DISCUSSION WITH PHARMA
USE OF FUNDS
NOT TO BE REPRODUCED WITHOUT PERMISSION OF RR MEDSCIENCES PTY LTD
Post mastectomy: NP
Rhinoplasty:
Traumatic Injury
Operations
RR MEDSCIENCES IS DEDICATED TO TRANSFORMATIVE MEDICINE
WE INVITE YOU TO JOIN US ON THIS JOURNEY
NOT TO BE REPRODUCED WITHOUT PERMISSION OF RR MEDSCIENCES PTY LTD
NOT TO BE REPRODUCED WITHOUT PERMISSION OF RR MEDSCIENCES PTY LTD